Principal Financial Group Inc Beam Therapeutics Inc. Transaction History

Principal Financial Group Inc

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 29, 2024	SELL	$21.22 - $32.66 $170,141 - $261,867	-8,018 Reduced 43.53%	10,400 $243,000
Q1 2024 Apr 29, 2024	BUY	$23.46 - $45.07 $18,509 - $35,560	789 Added 4.48%	18,418 $608,000
Q4 2023 Feb 07, 2024	BUY	$17.69 - $30.76 $5,023 - $8,735	284 Added 1.64%	17,629 $479,000
Q3 2023 Nov 02, 2023	BUY	$23.01 - $32.46 $437 - $616	19 Added 0.11%	17,345 $417,000
Q2 2023 Aug 07, 2023	BUY	$29.32 - $35.99 $12,343 - $15,151	421 Added 2.49%	17,326 $553,000
Q1 2023 May 09, 2023	SELL	$30.15 - $48.79 $33,195 - $53,717	-1,101 Reduced 6.11%	16,905 $517,000
Q4 2022 Feb 09, 2023	BUY	$36.73 - $51.6 $32,873 - $46,182	895 Added 5.23%	18,006 $704,000
Q3 2022 Nov 09, 2022	SELL	$39.79 - $70.31 $18,382 - $32,483	-462 Reduced 2.63%	17,111 $816,000
Q2 2022 Aug 10, 2022	SELL	$29.86 - $62.36 $113,318 - $236,656	-3,795 Reduced 17.76%	17,573 $681,000
Q1 2022 May 09, 2022	BUY	$53.73 - $82.16 $18,859 - $28,838	351 Added 1.67%	21,368 $1.23 Million
Q4 2021 Feb 09, 2022	SELL	$68.02 - $99.06 $383,088 - $557,905	-5,632 Reduced 21.13%	21,017 $1.68 Million
Q3 2021 Nov 09, 2021	BUY	$84.37 - $133.6 $485,718 - $769,135	5,757 Added 27.56%	26,649 $2.32 Million
Q2 2021 Aug 10, 2021	BUY	$64.12 - $128.71 $43,216 - $86,750	674 Added 3.33%	20,892 $2.69 Million
Q1 2021 May 10, 2021	SELL	$71.28 - $120.75 $40,201 - $68,103	-564 Reduced 2.71%	20,218 $1.62 Million
Q4 2020 Feb 08, 2021	BUY	$22.24 - $95.63 $462,191 - $1.99 Million	20,782 New	20,782 $1.7 Million

236

75.2M

438K

232K

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $1.78B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.